GHO Capital
GHO Capital (Global Healthcare Opportunities) is a London-based specialist healthcare investment firm founded in 2014, regulated by the FCA under firm reference number 1044842. It invests in companies with a European presence and global potential across outsourced pharma services, PharmaBio, MedTech and patient services, deploying capital through discrete buyout and growth funds. The firm closed Fund IV at over EUR 2.5bn in 2025, bringing assets under management to around EUR 9bn and making it the largest healthcare specialist private equity firm headquartered in Europe.
GHO Capital is a London buyout firm with €9.0B AUM, 16 active companies and 7 exits.
- ·5 exits in the last 5 years · consistent DPI cadence.
- ·Average hold across 7 realized deals: 5 years.
- ·Top sector focus: Pharma (26% of portfolio).
- ·Fund cadence: ~3Y between vintages · last raise 2025.
Sector breakdown
23 companiesGeography breakdown
6 geographiesKey facts
Recent exits
GHO Capital sold Biocare Medical to Agilent Technologies in 2026 after 5 years.
GHO Capital sold VISUfarma to Lupin in 2026 after 10 years.
GHO Capital sold FairJourney Biologics to Partners Group in 2024 after 4 years.
GHO Capital sold BioAgilytix to Cinven in 2021 after 3 years.
Coverage notes
4 funds tracked, 23 portfolio companies (16 active · 7 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund GHO Capital has raised, with its portfolio companies. Hand-checked from public filings.
GHO Capital IV LPBuyout2025€2.5B3 assetsBuyout2025 · 1yr€2.5B3–
Unrealized
3 held| Company | Entry |
|---|---|
| Avid Bioservices Biotech · US | 2025 |
| FotoFinder Systems MedTech · Germany | 2025 |
| Scientist.com HealthTech · US | 2025 |
GHO Capital III LPBuyout2021€2.0B8 assets1 exitsBuyout2021 · 5yr€2.0B81
Unrealized
8 held| Company | Entry |
|---|---|
| Alcami Corporation Pharma · US | 2022 |
| Clearview Healthcare Partners Business Services · US | 2021 |
| Envision Pharma Healthcare · UK | 2021 |
| Genesis Research HealthTech · US | 2021 |
| Roslinct Biotech · UK | 2021 |
| Sanner MedTech · Germany | 2022 |
| Sapio Sciences HealthTech · US | 2022 |
| Velocity Clinical Research HealthTech · US | 2021 |
Realized
1 exit| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Biocare Medical MedTech · US | 2021 | 2026 | Trade Sale | Agilent Technologies | – |
GHO Capital Fund II LPBuyout2019€975M3 assets1 exitsBuyout2019 · 7yr€975M31
Unrealized
3 held| Company | Entry |
|---|---|
| Ardena Pharma · Belgium | 2020 |
| Sterling Pharma Solutions Pharma · UK | 2019 |
| Validant Business Services · US | 2022 |
Realized
1 exit| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| FairJourney Biologics Biotech · Portugal | 2020 | 2024 | Secondary | Partners Group | – |
GHO Capital Fund I LPBuyout2015€660M2 assets5 exitsBuyout2015 · 11yr€660M25
Unrealized
2 held| Company | Entry |
|---|---|
| Linimed-Fazmed Healthcare · Germany | 2018 |
| Quotient Clinical Pharma · UK | 2015 |
Realized
5 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| BioAgilytix Biotech · US | 2018 | 2021 | Trade Sale | Cinven | – |
| Caprion Biosciences Biotech · Canada | 2016 | 2019 | Secondary | Arsenal Capital Partners | – |
| DNA Diagnostics Center Healthcare · US | 2015 | 2021 | Trade Sale | Eurofins | – |
| Quotient Sciences Pharma · UK | 2015 | 2019 | Secondary | Permira | – |
| VISUfarma Pharma · UK | 2016 | 2026 | Trade Sale | Lupin | – |
About GHO Capital
GHO Capital is an alternative investment platform with capital deployed across 4 active fund vehicles, headquartered in London. The firm deploys capital across European mid and small-cap businesses spanning healthcare and industrials.
Investment thesis
The platform combines complementary investment strategies, deploying capital across healthcare and industrials businesses in the United Kingdom and broader European market. Multi-strategy capital deployment enables flexibility across the business lifecycle, with the partnership culture supporting management teams through growth, transmission and selective M&A across multiple fund vintages and asset classes.
Recent activity
Realised exits across the current platform vintages remain limited, with the portfolio in active deployment and value-creation phase. The platform tracks 4 fund vehicles, 14 active portfolio companies and 0 realised exits across the strategy's history.
Frequently asked questions
- What investment strategy does GHO Capital focus on?
- GHO Capital focuses on Buyout, Growth strategies in the private equity space.
- How many portfolio companies does GHO Capital have?
- GHO Capital has 16 active portfolio companies and 7 completed exits and 4 funds tracked on GP Intel.
- Where is GHO Capital headquartered?
- GHO Capital is headquartered in London, United Kingdom.
- What is GHO Capital's assets under management?
- GHO Capital manages approximately €9.0B in assets under management.
- When was GHO Capital founded?
- GHO Capital was founded in 2014.
- What sectors does GHO Capital invest in?
- GHO Capital invests across Healthcare, Industrials.
- What are GHO Capital's recent exits?
- Recent realized exits by GHO Capital include: Biocare Medical (2026) to Agilent Technologies; VISUfarma (2026) to Lupin; FairJourney Biologics (2024) to Partners Group; BioAgilytix (2021) to Cinven; DNA Diagnostics Center (2021) to Eurofins; Caprion Biosciences (2019) to Arsenal Capital Partners; Quotient Sciences (2019) to Permira.
Similar firms
Other private equity firms tracked on GP Intel.
United Kingdom·€11.0B
United Kingdom·€11.0B
United Kingdom·€7.0B
United Kingdom·€7.0B
United Kingdom·€6.4B
United Kingdom·€11.7B
United Kingdom·€12.7B
United Kingdom·€4.8B
United Kingdom·€4.4B
United Kingdom·€4.4B
United Kingdom·€13.8B
United Kingdom·€4.1B